Carcinoma

In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival.

PMID 22274685 · Bolton et al., 2012 · Open in CIViC

In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC)

PMID 25847936 · Isakoff et al., 2015 · Open in CIViC

In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous … (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In patients with platinum-sensitive, recurrent serous ovarian cancer with BRCA mutation, median PFS was significantly longer in patients that received olaparib as compared to placebo (11.2 vs. 4.3 mon… (full text at CIViC)

PMID 24882434 · Ledermann et al., 2014 · Open in CIViC

In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative. Regardless of BRCA status, none showed objective response when treated with olaparib.

PMID 21862407 · Gelmon et al., 2011 · Open in CIViC

In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC)

PMID 24240112 · Pennington et al., 2014 · Open in CIViC

In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC)

PMID 24240112 · Pennington et al., 2014 · Open in CIViC

In a prespecified subgroup analysis of the randomized phase III TRITON3 trial, patients with metastatic castration-resistant prostate cancer harboring germline or somatic deleterious BRCA2 alterations… (full text at CIViC)

PMID 36795891 · Fizazi et al., 2023 · Open in CIViC

This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC)

PMID 38049622 · Fizazi et al., 2024 · Open in CIViC

In this 2017 study, the authors sought to characterize NUT carcinomas. They included a cohort of 12 aggressive malignant tumors with rearrangement of the NUTM1 gene, assessed by RT-PCR, FISH, positive… (full text at CIViC)

PMID 28643357 · Lemelle et al., 2017 · Open in CIViC

5 of 28 cases of undifferentiated carcinomas of the upper aerodigestive tract (UCUAT) not associated with EBV infection were found to have NUTM1 rearrangements suggesting NUT midline carcinoma may be… (full text at CIViC)

PMID 18391746 · Stelow et al., 2008 · Open in CIViC

Renal cell carcinoma (RCC) remains an intractable genitourinary malignancy. Resistance to chemotherapy or targeted therapies in RCC is presumably due to the complicated underlying molecular mechanisms… (full text at CIViC)

PMID 28391274 · Wu et al., 2017 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

Samples from 393 patients with NSCLC were evaluated for 3 SNPs in CBLB (rs1042852, rs2305035, and rs7649466). Genotypes rs7649466 and rs1042852 were not associated with a change in clinical outcome c… (full text at CIViC)

PMID 26732495 · Li et al., 2016 · Open in CIViC

The E3 ubiquitin ligase, CBLC, was identified as a candidate biomarker for olaparib sensitivity in a siRNA screen and further validated in-vitro in two breast carcinoma cell lines (MCF7 and HS578T). I… (full text at CIViC)

PMID 25883215 · Frankum et al., 2015 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

Case report of a 60-year old woman with lung adenocarcinoma. After negative testing for EGFR mutations and ALK translocations and failure of platinum-based chemotherapy she was enrolled on a nintedani… (full text at CIViC)

PMID 26787234 · Takeda et al., 2016 · Open in CIViC

Inceased copy number of CCND1 is associated with poorer overall survival.

PMID 17070615 · Gautschi et al., 2007 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

Three studies have found no significant survival impact for CCND1 in lung cancer.

PMID 17070615 · Gautschi et al., 2007 · Open in CIViC

Three studies have associated CCND1 expression with poorer survival.

PMID 17070615 · Gautschi et al., 2007 · Open in CIViC

Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.

PMID 16309541 · Thomas et al., 2005 · Open in CIViC

Study observed the effects of ribociclib (LEE011) on anaplastic thyroid cancer (ATC) and papillary thyroid cancer (PTC) cells. qRT-PCR found Cyclin D1 mRNA to have significantly higher expression in A… (full text at CIViC)

PMID 29306020 · Lee et al., 2018 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival.

PMID 20336784 · Nakayama et al., 2010 · Open in CIViC

A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors

PMID 27663592 · Au-Yeung et al., 2017 · Open in CIViC

Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma.

PMID 10224221 · Donnellan et al., 1999 · Open in CIViC

Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.

PMID 10224221 · Donnellan et al., 1999 · Open in CIViC

Sensitivity to durvalumab was tested in patients with triple-negative breast cancer (TNBC) harbouring CD274 gain/amplification. CD274 amplifications were noted in 42% (n=23) of the TNBC samples. Patie… (full text at CIViC)

PMID 33462450 · Bachelot et al., 2021 · Open in CIViC

This meta-analysis did not find a significant connection between expression of PD-L1 and overall survival in patients with NSCLC.

PMID 26664143 · Zhong et al., 2015 · Open in CIViC

In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study).

PMID 26313362 · Schmidt et al., 2015 · Open in CIViC